- Strategic Commercial Milestone: Marinomed has chosen its first product for the compounding market, Tacrolimus eyedrops. First revenues from partners are expected for Q4/2026 or beginning of 2027.
- Strong Clinical Validation: Feedback from a global network of leading ophthalmologists across USA and Europe confirms a high medical need for Tacrolimus to treat refractory ocular inflammation and to reduce long-term steroid dependency.
The full press release is available as download here: